Candel Therapeutics (CADL) Short term Debt (2020 - 2025)

Candel Therapeutics' Short term Debt history runs 4 years deep, the most recent figure standing at $4.2 million for Q3 2025.

• In Q3 2025, Short term Debt fell 57.11% year-over-year to $4.2 million; the TTM figure through Sep 2025 stood at $4.2 million (down 57.11% YoY), while the FY2024 annual figure was $9.9 million, up 11.27% from the prior year.
• Short term Debt came in at $4.2 million for Q3 2025 at Candel Therapeutics, down from $6.7 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.9 million in Q4 2024 to a low of $1.3 million in Q1 2023.
• A 3-year average of $7.2 million and a median of $8.9 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt soared 679.49% in 2024 and slumped 57.11% in 2025, its largest moves.
• Candel Therapeutics' Short term Debt stood at $8.9 million in 2023, then gained by 11.27% to $9.9 million in 2024, then tumbled by 57.3% to $4.2 million in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $4.2 million, $6.7 million, and $9.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.

Peer Comparison